Generics - Oncology

Filter

Current filters:

Oncology

Popular Filters

51 to 75 of 91 results

Sagent Pharma launches generic Zometa in USA; amends supply deal with Actavis

07-03-2013

Privately-held US specialty pharmaceutical company Sagent Pharmaceuticals has announced the approval…

ActavisGenericsMarkets & MarketingNorth AmericaNovartisOncologyProductionSagent PharmaceuticalsZometa

Indian patent appeal board upholds compulsory license on Bayer's Nexavar

05-03-2013

After much delay, the verdict into German pharmaceutical major Bayer's (BAYN: DE) appeal against the…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

Briefs: Ablynx inks research deal with Spirogen; Solent Pharma debuts

25-02-2013

Belgium drug developer Ablynx (Euronext Brussels: ABLX]) has entered into a research collaboration with…

AblynxGenericsidebenoneIdecortexLicensingMarkets & MarketingNeurologicalOncologyPharmaceuticalResearchSolent PharmaSpirogen

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

FDA approval of generic cancer drug Doxil is expected to help resolve shortage

06-02-2013

The US Food and Drug Administration has approved the first generic version of the cancer drug Doxil (doxorubicin…

DoxilGenericsJohnson & JohnsonLipodoxNorth AmericaOncologyRegulationSun Pharmaceutical Industries

ScinoPharm and Foresee Pharma set up JV for novel oncological peptide drugs

31-01-2013

Taiwanese drugmaker ScinoPharm (TWSE: 1789) and Foresee Pharmaceuticals, a Delaware, USA-based spin-out…

Asia-PacificForesee PharmaceuticalsGenericsleuprolideOncologyPharmaceuticalProductionResearchScinoPharm

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

MSF update on Novartis versus India, Supreme Court case

18-11-2012

Humanitarian health organization Medecins Sans Frontieres (MSF) says it continues to follow progress…

Asia-PacificGenericsGlivecLegalNovartisOncologyPatentsPharmaceutical

Survey reveals 98.9% of US physicians experienced cancer drug shortages in last 12 months

15-11-2012

The Community Oncology Alliance (COA), a US non-profit organization, announced the results of a drug…

GenericsHealthcareNorth AmericaOncologyPharmaceuticalPricing

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021

04-11-2012

Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021

28-10-2012

While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Hikma signs deal with GP Pharma for Lutrate 1 month in MENA region

22-10-2012

Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a license and supply agreement for the…

GenericsGP PharmHikma PharmaceuticalsLicensingLutrateOncologyRest of the World

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

India's IPAB rejects Bayer's "stay petition" regarding Nexavar

18-09-2012

Over the weekend, the Intellectual Property Appellate Board (IPAB) of Chennai, India, has dismissed the…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

51 to 75 of 91 results

COMPANY SPOTLIGHT

Menarini

Back to top